Leerink Partners Remains a Buy on Silk Road Medical (SILK)

In a report issued on May 2, Danielle Antalffy from Leerink Partners maintained a Buy rating on Silk Road Medical (SILKResearch Report). The company’s shares closed last Tuesday at $38.73.

According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 6.8% and a 46.6% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Silk Road Medical with a $47.00 average price target, representing a 18.4% upside. In a report issued on May 2, Wolfe Research also reiterated a Buy rating on the stock with a $48.00 price target.

See the top stocks recommended by analysts >>

Silk Road Medical’s market cap is currently $1.36B and has a P/E ratio of -26.95.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. The firm’s devices enable vascular access via a puncture adjacent to the collarbone instead of the traditional approach of accessing the vascular system through the groin. Its products include ENROUTE Transcarotid Neuroprotection & Stent System. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Read More on SILK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed